Inselspital Bern

Running trials

• Recruiting

  MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

  NCT07574047· Phase 2· Source

• Recruiting

  Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)

  NCT07309497· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Source

• Recruiting

  Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation

  NCT06954610· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Source

• Recruiting

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· Phase 3· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

  NCT07617610· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Source

• Enrolling by invitation

  RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS

  NCT07769983· Phase 1· Source

• Recruiting

  Reduce Tobacco Use in People Living With HIV in Switzerland

  NCT06789692· Source

• Recruiting

  Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma

  NCT06563362· Phase 2· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Source

• Recruiting

  Endometriosis and Pain Treatment by Intraoperative Administration of Low-dose Ketamine

  NCT06951802· Phase 4· Source

• Recruiting

  BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis

  NCT06221631· Source

• Active, not recruiting

  A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

  NCT06384261· Phase 2· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Source

• Active, not recruiting

  Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

  NCT05902169· Phase 3· Source

• Recruiting

  Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

  NCT05718323· Phase 2· Source

• Recruiting

  SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

  NCT05192980· Source

• Enrolling by invitation

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· Phase 3· Source

• Recruiting

  A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

  NCT05748171· Phase 2· Source

• Recruiting

  Hybrid Micro-macro Electrodes in Patients With Epilepsy

  NCT05335187· Source

• Active, not recruiting

  MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC

  NCT06095271· Source

• Recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

  NCT05623020· Phase 3· Source

• Active, not recruiting

  First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  NCT05361395· Phase 1· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Source

• Active, not recruiting

  A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

  NCT05094336· Phase 1/2· Source

• Recruiting

  High Dose Steroids in Children With Stroke

  NCT04873583· Phase 3· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Source

• Active, not recruiting

  Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

  NCT04604067· Phase 2· Source

• Active, not recruiting

  Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

  NCT04472949· Phase 2· Source

• Active, not recruiting

  Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

  NCT04763200· Source

• Active, not recruiting

  Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

  NCT04608318· Phase 3· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· Source

• Recruiting

  Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions

  NCT04449523· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Source

• Active, not recruiting

  Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

  NCT03965468· Phase 2· Source

• Recruiting

  Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions

  NCT05685069· Source

• Recruiting

  Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

  NCT03435796· Phase 2/3· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Source

• Recruiting

  Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

  NCT03643276· Phase 3· Source

• Recruiting

  Diagnosis of Tuberculosis in Swiss Children

  NCT03044509· Source

• Active, not recruiting

  International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

  NCT02724163· Phase 3· Source

• Active, not recruiting

  Prostate Cancer Biobank

  NCT04024475· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers5 recruiting
• Stroke5 recruiting
• Lung cancer3 recruiting
• Multiple myeloma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• HIV2 recruiting
• Colorectal cancer1 recruiting
• Cystic fibrosis1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Neuroblastoma1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting
• Sarcoma1 recruiting
• Tuberculosis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Evaluation of Correlations Between Volatile Organic Compounds and Venous Blood Glucose in Subjects With Type 2 Diabetes

  NCT07147010· Source

• Terminated

  The RECOVER IV Trial

  NCT05506449· Source

• Terminated

  Renal Denervation in Patients With Recurrent Atrial Fibrillation After Successful Pulmonary Vein Isolation

  NCT05817318· Source

• Recruiting

  A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

  NCT05789082· Phase 1/2· Source

• Terminated

  A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  NCT05317078· Phase 1· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Source

• Completed

  ProSPective Evaluation of Non-contrast sINe spiN Flat-dEtectoR CT for the Detection of Intracranial hemorrhageS

  NCT05458908· Source

• Completed

  A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

  NCT04998812· Phase 4· Source

• Completed

  A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

  NCT04760990· Source

• Completed

  Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

  NCT03993678· Phase 1/2· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Source

• Completed

  The MOCA I Study - Microvascular Obstruction with CoFI™ System Assessment

  NCT03654573· Phase 1· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source

• Completed

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· Phase 2· Source

• Completed

  Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection

  NCT02918955· Phase 3· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Source

• Completed

  A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

  NCT02508467· Phase 1· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Source

• Completed

  A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

  NCT02075840· Phase 3· Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Phase 3· Source

• Recruiting

  AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

  NCT02102165· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Source

• Completed

  Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery

  NCT01272050· Phase 3· Source

• Completed

  Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02

  NCT00963417· Source